SCHEMBL3735176

SCHEMBL3735176

O=P(Oc1ccccc1)(Oc1ccccc1)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA13 Q8N1Q1 1/20 0.40
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21117276 1.00 SRC (0.47) SRCL3MBTL1TDP1CYP3A4TSHR
SCHEMBL23349551 0.91 CYP3A4 (0.44) SRCL3MBTL1TDP1CYP3A4TSHR
SCHEMBL21119420 0.89 CYP3A4 (0.46) SRCL3MBTL1TDP1CYP3A4TSHR
SCHEMBL23349397 0.84 SRC (0.35) SRCL3MBTL1TDP1CYP3A4TSHR
SCHEMBL28913403 0.83 SRC (0.38) SRCL3MBTL1TDP1TSHRKDM4E
Triphenyl Phosphate SCHEMBL29001490 0.83 SRC (0.58) SRCL3MBTL1TDP1CYP3A4TSHR
Triphenyl Phosphate SCHEMBL1207087 0.83 SRC (0.58) SRCL3MBTL1TDP1CYP3A4TSHR
Triphenyl Phosphate SCHEMBL18116 0.82 SRC (0.64) SRCL3MBTL1TDP1CYP3A4TSHR
Triphenyl Phosphate SCHEMBL28557783 0.82 SRC (0.64) SRCL3MBTL1TDP1CYP3A4TSHR
Triphenyl Phosphate SCHEMBL483692 0.82 SRC (0.64) SRCL3MBTL1TDP1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111334800-A Novel PCB micro-etching solution and preparation method thereof 信丰正天伟电子科技有限公司 2020-06-26 CN claimed
EP-3684374-B1 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC (US) 2025-07-30 EP disclosed
CN-119153778-A Nonaqueous electrolyte and lithium ion battery comprising same 湖州昆仑亿恩科电池材料有限公司 2024-12-17 CN disclosed
CN-116444479-B Preparation method of high optical purity L-lactide 扬州大学 2024-08-02 CN disclosed
WO-2024017380-A1 TRICYCLIC-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 南京明德新药研发有限公司 2024-01-25 WO disclosed
CN-111194217-B 4 '-fluoro-2' -methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication 里伯赛恩斯有限责任公司 2024-01-12 CN disclosed
CN-116981672-A Macrocyclic compounds as CFTR modulators 爱杜西亚药品有限公司 2023-10-31 CN disclosed
EP-3744723-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND SHENZHEN TARGETRX INC (CN) 2023-10-18 EP disclosed
EP-3760632-B1 PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF Simcere pharmaceutical co ltd (CN) 2023-07-19 EP disclosed
CN-116444479-A Preparation method of high optical purity L-lactide 扬州大学 2023-07-18 CN disclosed
US-20140295566-A1 CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-02 US disclosed
US-8765384-B2 Carbohydrate-ligand conjugates and their application for the analysis of carbohydrate-protein interaction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-07-01 US disclosed
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed
EP-2061449-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES Leo Pharma A/S (DK) 2009-05-27 EP disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 WO disclosed
US-7320867-B2 Linker compound, ligand, and producing method thereof JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-01-22 US disclosed
US-20070287195-A1 Carohydrate-Ligand Conjugates and Their Application for the Analysis of Carbohydrate-Protein Interaction JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2007-12-13 US disclosed
EP-1726596-A1 SUGAR CHAIN LIGAND COMPOSITE AND METHOD OF ANALYZING PROTEIN WITH THE LIGAND COMPOSITE Japan Science and Technology Agency (JP) 2006-11-29 EP disclosed
US-20060030699-A1 Versatile linker compound and ligand, and method for preparation thereof NATIONAL UNIVERSITY CORPORATION KAGOSHIMA UNIVERSITY (JP) 2006-02-09 US disclosed
EP-1538156-A1 VERSATILE LINKER COMPOUND AND LIGAND, AND METHOD FOR PREPARATION THEREOF Japan Science and Technology Agency (JP) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R SRC 2379/4885L3MBTL1 2017/4885TDP1 4767/4885
US-20070287195-A1 Carohydrate-Ligand Conjugates and Their Application for the Analysis of Carbohydrate-Protein Interaction CA11, CNPY3, CACYBP SRC 1614/4885L3MBTL1 2698/4885TDP1 4792/4885
US-20140295566-A1 CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION CA11, CA14, OSTC SRC 1298/4885L3MBTL1 2940/4885TDP1 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.